USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences (USNA) reported third-quarter 2026 net sales of $206 million, down 4% year over year, and a net loss attributable to USANA of $5.6 million, compared with $6.5 million a year earlier. Adjusted EBITDA attributable to USANA was $12.1 million, down 13%; diluted loss per share was $0.30 versus $0.36.
Hiya sales rose 2% year over year to $32 million, while active monthly subscribers increased 18% sequentially to 195,500. Core Nutritional sales fell 3% to $171 million, though its operating margin was 4.1% versus 1.2% a year earlier; Rise sales were $4 million, down 45%. USANA generated $8 million of quarterly free cash flow and $36 million year to date, and ended October 3 with $179 million in cash and no debt.
Fiscal 2026 guidance now calls for consolidated net sales approaching $900 million, a net loss of $16 million and Adjusted EBITDA of $77 million. USANA also corrected second-quarter 2026 Adjusted EBITDA attributable to USANA from $27.8 million to $21.7 million after subtracting the $6.2 million share attributable to Hiya’s noncontrolling interest; reported GAAP results were unaffected.
USANA Health Sciences director Timothy E. Wood exercised 1,632 restricted stock units on October 22, 2026, receiving 1,632 common shares. On the same date, 408 common shares were delivered or withheld for payment of exercise price or tax liability at $14.52 per share. Wood held 3,263 restricted stock units following the transaction.
USANA Health Sciences Inc. director Frederic J. Winssinger exercised 1,632 restricted stock units into 1,632 shares of common stock on October 22, 2026. After the transaction, he reported 3,263 restricted stock units and 11,365 shares of common stock. Each restricted stock unit represents a contingent right to receive one share of common stock.
USANA HEALTH SCIENCES INC (USNA) director J. Scott Nixon exercised 1,632 restricted stock units, which converted into 1,632 common shares, on October 22, 2026. After the transaction, he directly held 13,077 common shares and 3,263 restricted stock units. Each unit represents a contingent right to receive one common share; no Rule 10b5-1 plan is reported.
USANA Health Sciences Inc. director Gilbert A. Fuller converted 1,632 restricted stock units into 1,632 shares of common stock on October 22, 2026. Each unit represents a contingent right to receive one common share. After the transaction, his reported direct holdings were 3,264 common shares and 3,263 restricted stock units.
USANA Health Sciences director Peggie Pelosi converted 1,632 restricted stock units into 1,632 common shares on October 22, 2026. Also on that date, 935 shares were delivered or withheld for payment of exercise price or tax liability at $14.52 per share. Pelosi had 3,263 restricted stock units following the conversion. No Rule 10b5-1 plan is reported.
John Turman Fleming, a director of USANA Health Sciences (USNA), converted 1,632 restricted stock units into 1,632 shares of common stock on October 22, 2026. After the transaction, his direct holdings were 3,263 restricted stock units and 7,494 shares of common stock. Each restricted stock unit represents a contingent right to receive one common share.
USANA Health Sciences (USNA) director Xia Ding reported exercising or converting 1,632 restricted stock units into 1,632 common shares on October 22, 2026. On the same date, 604 common shares were delivered or withheld for payment of exercise price or tax liability; the transaction lists a price of $14.52 per share. The reported resulting position was 3,263 restricted stock units. The units vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027, and each represents a contingent right to receive one common share.
USANA Health Sciences, Inc. amended its $75 million revolving credit facility on September 30, 2026, changing its EBITDA covenant, asset-sale limits and permitted Sydney property transactions. The facility matures on June 27, 2030.
Beginning with the fiscal quarter ending October 3, 2026, USANA must maintain at least $100 million of Consolidated EBITDA for each trailing four-fiscal-quarter period. The minimum falls to $70 million if lenders’ aggregate Revolving Exposure is $50 million or less on the period’s last day. The annual general asset-sale basket rises from $500,000 to $2.5 million in aggregate book value. The amendment also permits USANA Australia Pty, Ltd to sell real property in Sydney and use the net proceeds as it determines appropriate in its reasonable business judgment. Sale-and-leaseback transactions remain prohibited, subject to the stated exceptions. The loan parties reaffirmed their obligations and liens and confirmed that no default or event of default exists.
USANA Health Sciences Inc. has a significant shareholder disclosure from Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation. As of June 30, 2026, these entities report beneficial ownership of 958,520 shares of USANA common stock, par value $0.001 per share.
This position represents 5.19% of the outstanding common stock. Renaissance reports sole voting power and sole dispositive power over all 958,520 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of these securities.